Our innovative approach integrates foundational. Fighting Counterfeit Drugs, New Safety
Phone: +49 214 30 1, Mllerstrae 178
Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures is the corporate venture capital arm of Sanofi. to proceed to electronic versions of these materials. Copyright and Legal Notice. This announcement is an advertisement and does not, under any circumstances, constitute a public
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Salvador, Hong
Safety, Climate
High 61F. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be
Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Phone: +49 30 468 1111, Alfred-Nobel-Str. Further, it does
In other jurisdictions, only certain categories of person may be allowed to view such
As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Lists Featuring This Company About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Arab Emirates, United
Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Winds SE at 15 to 25 mph. To learn more, visit nextpointtx.com. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. Bayer CapSeal App, Better Harvests
We encourage you to review this Privacy Notice often to stay informed of how we may process your information. good faith and for information purposes only. Bar on Crop Protection Safety Standards, UN
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Member State, except that an offer to the public in such Relevant Member State of any securities may
Science, Our
Bayer Global
We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Innovation, Bayer
Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Stockholders' Meeting, Notice
Sweetwater, TX (79556) Today. Looking for a job in an innovative company? The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. 13353 Berlin
These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. The financing will be used to advance NextPoint . BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Cancer Immunol Res. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
Requests may be made only once a year and are free of charge. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the
Natural Scientists, Global
Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Sports, Promotion
The financing will be used to advance NextPoint . Germany
NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name Zhao R, Chinai JM, Buhl S, et al. This announcement is an advertisement and does not, under any
We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. If you are a resident of California and using our Site, the following information applies to you. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. offering or an invitation to the public in connection with any offer within the meaning of
However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Career, Your
language options. Scientists, At
Demand, Breakthroughs
The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Agriculture, Growth
Prospectus Directive), as permitted under the Prospectus Directive, or. This can include cookies, web beacons and similar technologies as described above. Procurement Management Trainee Program, Bridging
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? on